Product
TY-1091
1 clinical trial
4 indications
Indication
Medullary Thyroid CarcinomaIndication
Papillary Thyroid CancerIndication
CancerClinical trial
A Phase I/II Study of Oral TY-1091 in Adult Patients With Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, RET-Mutation Medullary Thyroid Cancer, and Other Tumors With RET AlterationsStatus: Recruiting, Estimated PCD: 2025-06-01